👪

Inheritance

1

Autosomal Dominant HP:0000006

BPES is predominantly inherited as an autosomal dominant disorder caused by heterozygous FOXL2 variants, although de novo sporadic presentations also occur.

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:33806295 SUPPORT Other

"It shows autosomal dominant inheritance but can also occur sporadically."

Review-level evidence supports autosomal dominant inheritance with possible sporadic presentations.

◆

Subtypes

2

Type I (with primary ovarian insufficiency)

Type I BPES includes the congenital eyelid malformation complex together with primary ovarian insufficiency and female infertility risk. Truncating FOXL2 variants are enriched in this subtype, but genotype alone does not completely predict ovarian outcome.

Show evidence (2 references)

PMID:41555764 SUPPORT Human Clinical

"Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), caused by FOXL2 variants, has been divided into two subtypes by eyelid abnormalities with (BPES-I) or without (BPES-II) primary ovarian insufficiency (POI)."

Supports the disease-root split of BPES into Type I and Type II using ovarian involvement as the defining distinction.

PMID:41555764 SUPPORT Human Clinical

"The proportion of truncation variants was significantly higher in patients with BPES-I (73.8%, 48/65) than in those with BPES-II (19.6%, 19/97)."

Supports enrichment of truncating FOXL2 variants in the more severe Type I subtype.

Type II (isolated eyelid malformation)

Type II BPES is restricted to the congenital eyelid phenotype without systemic ovarian involvement. Polyalanine expansions and protein-elongating variants are often reported in this subtype, although subtype assignment cannot be made from genotype alone.

Show evidence (2 references)

PMID:41555764 SUPPORT Human Clinical

"Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), caused by FOXL2 variants, has been divided into two subtypes by eyelid abnormalities with (BPES-I) or without (BPES-II) primary ovarian insufficiency (POI)."

Supports the disease-root split of BPES into Type I and Type II using absence of ovarian involvement to define Type II.

PMID:33806295 SUPPORT Other

"Depending on the mutation, two phenotypic subtypes have been described, both involving the same craniofacial features: type I, which is associated with premature ovarian failure (POF), and type II, which has no systemic features."

Review-level evidence supports Type II as the isolated oculofacial subtype without systemic features.

⚙

Pathophysiology

4

FOXL2-dependent eyelid developmental dysregulation

Pathogenic FOXL2 variants impair transcriptional control of eyelid developmental targets, including OSR2, and disrupt eyelid morphogenesis. This provides a mechanistic bridge from FOXL2 dysfunction to the congenital blepharophimosis-ptosis-epicanthus inversus phenotype shared by both BPES subtypes.

eyelid development in camera-type eye link ↓ DECREASED regulation of transcription by RNA polymerase II link ⚠ ABNORMAL

eyelid link

Downstream

Congenital eyelid malformation complex Impaired eyelid developmental gene regulation produces the characteristic BPES oculofacial phenotype.

Show evidence (1 reference)

PMID:33796131 SUPPORT In Vitro

"Furthermore, the missenses variants c.307C > T; p.(Arg103Cys), c.311A > C; p.(His104Pro), and c.320G > A; p.(Ser107Asn) were not able to transactivate OSR2, which is consistent with the eyelid malformation in these patients."

Functional data support FOXL2-driven disruption of eyelid developmental transcriptional programs through failed OSR2 transactivation.

FOXL2 dysfunction in ovarian reserve maintenance

In affected females with Type I BPES, FOXL2 dysfunction impairs granulosa cell transcriptional regulation and ovarian follicle biology, producing diminished ovarian reserve, adverse assisted reproduction outcomes, and risk for premature ovarian insufficiency.

granulosa cell link

ovarian follicle development link ↓ DECREASED negative regulation of transcription by RNA polymerase II link ↓ DECREASED

ovary link

Downstream

Diminished ovarian reserve FOXL2-related granulosa-cell dysfunction reduces ovarian reserve and predisposes to Type I BPES ovarian failure.

Show evidence (2 references)

PMID:31823134 SUPPORT In Vitro

"The mutation abolished the transcriptional repression of FOXL2 on the promoters of CYP19A1 and CCND2 genes, as shown by luciferase reporter assays."

Supports loss of FOXL2 transcriptional repression in ovarian regulatory circuits relevant to infertility and ovarian dysfunction.

PMID:35574016 SUPPORT Human Clinical

"Compared to non-mutation group, patients with FOXL2 mutations had elevated levels of FSH (P=0.007), decreased AMH levels (P=0.012) and less AFC (P=0.015)."

Clinical ovarian reserve markers support the link between FOXL2-mutant BPES and reduced ovarian reserve.

Variant-class-dependent subtype severity

FOXL2 variant class influences clinical severity at the disease-root level: truncating variants are enriched in BPES-I, whereas milder in-frame polyalanine-region changes more often track with BPES-II. The relationship is probabilistic rather than deterministic.

Show evidence (2 references)

PMID:41555764 SUPPORT Human Clinical

"The proportion of truncation variants was significantly higher in patients with BPES-I (73.8%, 48/65) than in those with BPES-II (19.6%, 19/97)."

Supports subtype-severity differences tied to FOXL2 variant class.

PMID:33806295 SUPPORT Other

"However, the BPES subtype cannot be determined genetically, necessitating informed genetic counselling and careful discussion of family planning advice in view of the associated POF particularly as the patient may still be a child."

Review-level evidence cautions that genotype alone does not fully determine BPES subtype.

Polyalanine expansion and FOXL2 protein mislocalization

FOXL2 polyalanine-tract expansions and selected missense variants can disrupt normal nuclear localization and promote aggregation or altered intranuclear mobility. This provides a mechanistic route distinct from straightforward truncating-variant haploinsufficiency and is relevant to the BPES-II-enriched polyalanine variant class.

nucleus link

Show evidence (2 references)

PMID:33796131 SUPPORT In Vitro

"Human FOXL2 belongs to the winged helix/forkhead transcription factor family, coding 376 amino acids, which contains a 110 amino acid DNA-binding fork head domain (forkhead domain, FHD) and a polyalanine tract of 14 residues (poly-Ala), whose expansions would cause mislocation, aggregation, and..."

Review and functional context support polyalanine expansion as a mislocalization/aggregation mechanism.

PMID:41555764 SUPPORT Human Clinical

"The most frequent (24.0%, 132/549) variant was p.A225_A234dup."

Large genotype review identifies the recurrent polyalanine expansion variant as the most frequent FOXL2 pathogenic/likely pathogenic variant.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

Referential integrity issues (2):

Target 'Congenital eyelid malformation complex' (from 'FOXL2-dependent eyelid developmental dysregulation') not found in named elements
Target 'Diminished ovarian reserve' (from 'FOXL2 dysfunction in ovarian reserve maintenance') not found in named elements

●

Phenotypes

10

Eye 2

Ptosis Ptosis (HP:0000508)

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"is defined by a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus."

GeneReviews summary supports ptosis as a cardinal diagnostic feature of BPES.

Strabismus Strabismus (HP:0000486)

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"Other ophthalmic manifestations that can be associated with BPES include dysplastic eyelids, lacrimal duct anomalies, strabismus, refractive errors, and amblyopia."

GeneReviews summary supports strabismus as an associated ophthalmic feature of BPES.

Genitourinary 2

Premature ovarian insufficiency Premature ovarian insufficiency (HP:0008209)

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"BPES type I includes the four major features and primary ovarian insufficiency; BPES type II includes only the four major features."

GeneReviews summary supports premature ovarian insufficiency as the defining extraocular phenotype of Type I BPES.

Female infertility Female infertility (HP:0008222)

Show evidence (1 reference)

PMID:31823134 SUPPORT Human Clinical

"There are two clinical types of BPES: type I patients have eyelid abnormalities accompanied by infertility in affected females, while type II patients only display eyelid malformations."

Human clinical evidence supports female infertility as a hallmark feature of Type I BPES.

Other 6

Blepharophimosis Blepharophimosis (HP:0000581)

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"is defined by a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus."

GeneReviews summary supports blepharophimosis as a cardinal diagnostic feature of BPES.

Epicanthus inversus Epicanthus inversus (HP:0000537)

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"is defined by a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus."

GeneReviews summary supports epicanthus inversus as a cardinal diagnostic feature of BPES.

Telecanthus Telecanthus (HP:0000506)

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"is defined by a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus."

GeneReviews summary supports telecanthus as a cardinal diagnostic feature of BPES.

Amblyopia Amblyopia (HP:0000646)

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"Other ophthalmic manifestations that can be associated with BPES include dysplastic eyelids, lacrimal duct anomalies, strabismus, refractive errors, and amblyopia."

GeneReviews summary supports amblyopia as an associated ophthalmic feature of BPES.

Refractive Errors Abnormality of refraction (HP:0000539)

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"Other ophthalmic manifestations that can be associated with BPES include dysplastic eyelids, lacrimal duct anomalies, strabismus, refractive errors, and amblyopia."

GeneReviews lists refractive errors among ophthalmic manifestations associated with BPES.

Lacrimal Duct Anomalies Abnormal lacrimal duct morphology (HP:0011481)

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"Other ophthalmic manifestations that can be associated with BPES include dysplastic eyelids, lacrimal duct anomalies, strabismus, refractive errors, and amblyopia."

GeneReviews lists lacrimal duct anomalies among ophthalmic manifestations associated with BPES.

🧬

Genetic Associations

1

FOXL2 (Causative)

Autosomal Dominant

Show evidence (2 references)

PMID:33806295 SUPPORT Other

"Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) is a craniofacial disorder caused by heterozygous variants of the forkhead box L2 (FOXL2) gene."

Directly identifies heterozygous FOXL2 variants as the causal basis of BPES.

PMID:41555764 SUPPORT Human Clinical

"Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), caused by FOXL2 variants, has been divided into two subtypes by eyelid abnormalities with (BPES-I) or without (BPES-II) primary ovarian insufficiency (POI)."

Connects FOXL2 causality to the clinically important BPES subtype structure.

💊

Treatments

7

Medial canthoplasty

Action: surgical procedure MAXO:0000004

Surgical correction of the medial canthal complex is used to address blepharophimosis, epicanthus inversus, and telecanthus, typically as the first stage of eyelid reconstruction.

Target Phenotypes: Blepharophimosis ↗ Epicanthus inversus ↗ Telecanthus ↗

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"Eyelid surgery traditionally involves a medial canthoplasty for correction of the blepharophimosis, epicanthus inversus, and telecanthus at age three to five years, typically followed a year later by ptosis correction."

GeneReviews supports medial canthoplasty as part of standard staged reconstruction for the core BPES eyelid phenotype.

Frontalis suspension surgery

Action: surgical procedure MAXO:0000004

Surgical ptosis correction, including frontalis suspension approaches, is used to address co-existing blepharoptosis after medial canthal correction. In the traditional staged approach, ptosis correction follows medial canthoplasty by about one year.

Target Phenotypes: Ptosis ↗

Show evidence (1 reference)

PMID:35590300 SUPPORT Human Clinical

"All cases were subjected to by C plasty with medial and lateral canthoplasty for correction of epicanthus and telecanthus correction followed by frontalis suspension surgery to correct the co-existing blepharoptosis."

Retrospective surgical series supports staged frontalis suspension to correct BPES-associated ptosis.

Amblyopia Prevention and Refractive Management

Action: supportive care MAXO:0000950

Ophthalmic follow-up should include visual acuity testing, refraction, and treatment of amblyopia risk through optical correction, occlusion therapy, and strabismus management when indicated.

Target Phenotypes: Amblyopia ↗ Refractive error ↗

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"Ophthalmic follow up depends on age, procedures performed in the past, and results of visual acuity testing."

GeneReviews supports ongoing ophthalmic follow-up tied to visual acuity and prior procedures.

Hormone replacement therapy

Action: hormone replacement therapy Ontology label: Hormone Replacement Therapy NCIT:C15599

Hormone replacement therapy is used to manage Type I BPES-associated premature ovarian insufficiency and hypoestrogenic sequelae.

Target Phenotypes: Premature ovarian insufficiency ↗

Show evidence (1 reference)

PMID:20301614 SUPPORT Other

"Primary ovarian insufficiency is managed by hormone replacement therapy; fertility is addressed with reproductive technologies such as embryo donation, egg donation, and cryopreservation strategies."

GeneReviews supports hormone replacement therapy as standard management for BPES-associated ovarian insufficiency.

Assisted reproductive technology

Action: assisted reproductive technology Ontology label: Assisted Reproductive Technology NCIT:C93282

Assisted reproductive technologies are used for fertility planning and treatment in affected women with Type I BPES. Counseling should include fertility preservation options such as oocyte or embryo cryopreservation before ovarian reserve declines, while recognizing that outcomes are heterogeneous across FOXL2 mutation classes.

Target Phenotypes: Female infertility ↗

Show evidence (1 reference)

PMID:35574016 SUPPORT Human Clinical

"Twenty-one women with BPES were screened for mutations in the FOXL2 gene and underwent assisted reproductive technology (ART) treatment."

Human clinical study directly documents use of assisted reproductive technology in women with BPES.

Bone Health Monitoring in Primary Ovarian Insufficiency

Action: supportive care MAXO:0000950

Type I females with hypoestrogenism from primary ovarian insufficiency need monitoring and prevention of estrogen-deficiency sequelae, including bone health assessment and coordination with hormone replacement therapy.

Target Phenotypes: Premature ovarian insufficiency ↗

Show evidence (1 reference)

PMID:24905063 SUPPORT Human Clinical

"Women with primary ovarian insufficiency have significantly lower serum estradiol and T levels compared with regularly menstruating women. They also have significantly reduced bone mineral density (BMD)."

Primary ovarian insufficiency is associated with reduced bone mineral density, supporting bone-health monitoring in Type I BPES with POI.

Genetic Counseling

Action: genetic counseling MAXO:0000079

Counsel affected individuals and families about autosomal dominant inheritance, the 50% transmission risk to offspring, variable Type I/II expressivity, de novo cases, and availability of prenatal or preimplantation genetic testing once the familial variant is known.

Show evidence (2 references)

PMID:20301614 SUPPORT Other

"Each child of an individual with BPES has a 50% chance of inheriting the pathogenic variant."

GeneReviews supports counseling about autosomal dominant recurrence risk.

PMID:20301614 SUPPORT Other

"Once the BPES-causing pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for BPES are possible."

GeneReviews supports reproductive genetic counseling after the familial FOXL2 pathogenic variant is identified.

{ }

Source YAML

click to show

name: Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome
creation_date: "2026-04-14T07:42:43Z"
updated_date: "2026-04-14T07:56:36Z"
category: Mendelian
description: >
  Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) is an
  autosomal dominant FOXL2-related craniofacial disorder defined by a congenital
  eyelid malformation complex of blepharophimosis, ptosis, epicanthus inversus,
  and telecanthus. This entry is curated at the disease-root level and separates
  BPES into subtype I, which includes primary ovarian insufficiency in affected
  females, and subtype II, which is limited to the oculofacial phenotype.
disease_term:
  preferred_term: blepharophimosis, ptosis, and epicanthus inversus syndrome
  term:
    id: MONDO:0007201
    label: blepharophimosis, ptosis, and epicanthus inversus syndrome
synonyms:
- BPES
- Blepharophimosis syndrome
parents:
- Craniofacial Disorder
- Congenital Eye Disorder
notes: >-
  This entry intentionally treats BPES as a root disease with explicit subtype
  structure (Type I and Type II) rather than flattening ovarian involvement into
  a single undifferentiated phenotype bucket.
has_subtypes:
- name: Type I
  display_name: Type I (with primary ovarian insufficiency)
  description: >
    Type I BPES includes the congenital eyelid malformation complex together
    with primary ovarian insufficiency and female infertility risk. Truncating
    FOXL2 variants are enriched in this subtype, but genotype alone does not
    completely predict ovarian outcome.
  evidence:
  - reference: PMID:41555764
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), caused by FOXL2 variants, has been divided into two subtypes by eyelid abnormalities with (BPES-I) or without (BPES-II) primary ovarian insufficiency (POI)."
    explanation: Supports the disease-root split of BPES into Type I and Type II using ovarian involvement as the defining distinction.
  - reference: PMID:41555764
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proportion of truncation variants was significantly higher in patients with BPES-I (73.8%, 48/65) than in those with BPES-II (19.6%, 19/97)."
    explanation: Supports enrichment of truncating FOXL2 variants in the more severe Type I subtype.
- name: Type II
  display_name: Type II (isolated eyelid malformation)
  description: >
    Type II BPES is restricted to the congenital eyelid phenotype without
    systemic ovarian involvement. Polyalanine expansions and protein-elongating
    variants are often reported in this subtype, although subtype assignment
    cannot be made from genotype alone.
  evidence:
  - reference: PMID:41555764
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), caused by FOXL2 variants, has been divided into two subtypes by eyelid abnormalities with (BPES-I) or without (BPES-II) primary ovarian insufficiency (POI)."
    explanation: Supports the disease-root split of BPES into Type I and Type II using absence of ovarian involvement to define Type II.
  - reference: PMID:33806295
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Depending on the mutation, two phenotypic subtypes have been described, both involving the same craniofacial features: type I, which is associated with premature ovarian failure (POF), and type II, which has no systemic features."
    explanation: Review-level evidence supports Type II as the isolated oculofacial subtype without systemic features.
inheritance:
- name: Autosomal Dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >
    BPES is predominantly inherited as an autosomal dominant disorder caused by
    heterozygous FOXL2 variants, although de novo sporadic presentations also
    occur.
  evidence:
  - reference: PMID:33806295
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It shows autosomal dominant inheritance but can also occur sporadically."
    explanation: Review-level evidence supports autosomal dominant inheritance with possible sporadic presentations.
genetic:
- name: FOXL2
  gene_term:
    preferred_term: FOXL2
    term:
      id: hgnc:1092
      label: FOXL2
  association: Causative
  features: >
    FOXL2 encodes a forkhead transcription factor. Heterozygous pathogenic
    variants cause BPES and can perturb eyelid developmental gene regulation and
    ovarian reserve maintenance. Truncating variants are enriched in Type I,
    while polyalanine expansions and protein-elongating variants are often
    associated with Type II, but genotype-phenotype correlation remains
    incomplete.
  inheritance:
  - name: Autosomal Dominant
  evidence:
  - reference: PMID:33806295
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) is a craniofacial disorder caused by heterozygous variants of the forkhead box L2 (FOXL2) gene."
    explanation: Directly identifies heterozygous FOXL2 variants as the causal basis of BPES.
  - reference: PMID:41555764
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), caused by FOXL2 variants, has been divided into two subtypes by eyelid abnormalities with (BPES-I) or without (BPES-II) primary ovarian insufficiency (POI)."
    explanation: Connects FOXL2 causality to the clinically important BPES subtype structure.
pathophysiology:
- name: FOXL2-dependent eyelid developmental dysregulation
  description: >
    Pathogenic FOXL2 variants impair transcriptional control of eyelid
    developmental targets, including OSR2, and disrupt eyelid morphogenesis.
    This provides a mechanistic bridge from FOXL2 dysfunction to the congenital
    blepharophimosis-ptosis-epicanthus inversus phenotype shared by both BPES
    subtypes.
  gene:
    preferred_term: FOXL2
    modifier: DECREASED
    term:
      id: hgnc:1092
      label: FOXL2
  biological_processes:
  - preferred_term: eyelid development in camera-type eye
    term:
      id: GO:0061029
      label: eyelid development in camera-type eye
    modifier: DECREASED
  - preferred_term: regulation of transcription by RNA polymerase II
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
    modifier: ABNORMAL
  locations:
  - preferred_term: eyelid
    term:
      id: UBERON:0001711
      label: eyelid
  evidence:
  - reference: PMID:33796131
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Furthermore, the missenses variants c.307C > T; p.(Arg103Cys), c.311A > C; p.(His104Pro), and c.320G > A; p.(Ser107Asn) were not able to transactivate OSR2, which is consistent with the eyelid malformation in these patients."
    explanation: Functional data support FOXL2-driven disruption of eyelid developmental transcriptional programs through failed OSR2 transactivation.
  downstream:
  - target: Congenital eyelid malformation complex
    description: Impaired eyelid developmental gene regulation produces the characteristic BPES oculofacial phenotype.
- name: FOXL2 dysfunction in ovarian reserve maintenance
  description: >
    In affected females with Type I BPES, FOXL2 dysfunction impairs granulosa
    cell transcriptional regulation and ovarian follicle biology, producing
    diminished ovarian reserve, adverse assisted reproduction outcomes, and
    risk for premature ovarian insufficiency.
  gene:
    preferred_term: FOXL2
    modifier: DECREASED
    term:
      id: hgnc:1092
      label: FOXL2
  cell_types:
  - preferred_term: granulosa cell
    term:
      id: CL:0000501
      label: granulosa cell
  biological_processes:
  - preferred_term: ovarian follicle development
    term:
      id: GO:0001541
      label: ovarian follicle development
    modifier: DECREASED
  - preferred_term: negative regulation of transcription by RNA polymerase II
    term:
      id: GO:0000122
      label: negative regulation of transcription by RNA polymerase II
    modifier: DECREASED
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  evidence:
  - reference: PMID:31823134
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The mutation abolished the transcriptional repression of FOXL2 on the promoters of CYP19A1 and CCND2 genes, as shown by luciferase reporter assays."
    explanation: Supports loss of FOXL2 transcriptional repression in ovarian regulatory circuits relevant to infertility and ovarian dysfunction.
  - reference: PMID:35574016
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared to non-mutation group, patients with FOXL2 mutations had elevated levels of FSH (P=0.007), decreased AMH levels (P=0.012) and less AFC (P=0.015)."
    explanation: Clinical ovarian reserve markers support the link between FOXL2-mutant BPES and reduced ovarian reserve.
  downstream:
  - target: Diminished ovarian reserve
    description: FOXL2-related granulosa-cell dysfunction reduces ovarian reserve and predisposes to Type I BPES ovarian failure.
- name: Variant-class-dependent subtype severity
  description: >
    FOXL2 variant class influences clinical severity at the disease-root level:
    truncating variants are enriched in BPES-I, whereas milder in-frame
    polyalanine-region changes more often track with BPES-II. The relationship
    is probabilistic rather than deterministic.
  evidence:
  - reference: PMID:41555764
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proportion of truncation variants was significantly higher in patients with BPES-I (73.8%, 48/65) than in those with BPES-II (19.6%, 19/97)."
    explanation: Supports subtype-severity differences tied to FOXL2 variant class.
  - reference: PMID:33806295
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, the BPES subtype cannot be determined genetically, necessitating informed genetic counselling and careful discussion of family planning advice in view of the associated POF particularly as the patient may still be a child."
    explanation: Review-level evidence cautions that genotype alone does not fully determine BPES subtype.
- name: Polyalanine expansion and FOXL2 protein mislocalization
  description: >
    FOXL2 polyalanine-tract expansions and selected missense variants can
    disrupt normal nuclear localization and promote aggregation or altered
    intranuclear mobility. This provides a mechanistic route distinct from
    straightforward truncating-variant haploinsufficiency and is relevant to
    the BPES-II-enriched polyalanine variant class.
  gene:
    preferred_term: FOXL2
    modifier: ABNORMAL
    term:
      id: hgnc:1092
      label: FOXL2
  cellular_components:
  - preferred_term: nucleus
    term:
      id: GO:0005634
      label: nucleus
  evidence:
  - reference: PMID:33796131
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Human FOXL2 belongs to the winged helix/forkhead transcription factor family, coding 376 amino acids, which contains a 110 amino acid DNA-binding fork head domain (forkhead domain, FHD) and a polyalanine tract of 14 residues (poly-Ala), whose expansions would cause mislocation, aggregation, and intranuclear mobility of the protein"
    explanation: >
      Review and functional context support polyalanine expansion as a
      mislocalization/aggregation mechanism.
  - reference: PMID:41555764
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent (24.0%, 132/549) variant was p.A225_A234dup."
    explanation: >
      Large genotype review identifies the recurrent polyalanine expansion
      variant as the most frequent FOXL2 pathogenic/likely pathogenic variant.
phenotypes:
- category: Craniofacial
  name: Blepharophimosis
  description: Congenital shortening of the horizontal palpebral fissures is one of the four cardinal BPES eyelid features.
  phenotype_term:
    preferred_term: Blepharophimosis
    term:
      id: HP:0000581
      label: Blepharophimosis
  diagnostic: true
  subtypes:
  - Type I
  - Type II
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "is defined by a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus."
    explanation: GeneReviews summary supports blepharophimosis as a cardinal diagnostic feature of BPES.
- category: Ocular
  name: Ptosis
  description: Bilateral congenital ptosis is part of the cardinal BPES eyelid complex and can interfere with visual development.
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  diagnostic: true
  subtypes:
  - Type I
  - Type II
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "is defined by a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus."
    explanation: GeneReviews summary supports ptosis as a cardinal diagnostic feature of BPES.
- category: Craniofacial
  name: Epicanthus inversus
  description: Epicanthus inversus is part of the defining congenital eyelid phenotype in both BPES subtypes.
  phenotype_term:
    preferred_term: Epicanthus inversus
    term:
      id: HP:0000537
      label: Epicanthus inversus
  diagnostic: true
  subtypes:
  - Type I
  - Type II
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "is defined by a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus."
    explanation: GeneReviews summary supports epicanthus inversus as a cardinal diagnostic feature of BPES.
- category: Craniofacial
  name: Telecanthus
  description: Telecanthus completes the four-feature congenital eyelid complex that defines BPES.
  phenotype_term:
    preferred_term: Telecanthus
    term:
      id: HP:0000506
      label: Telecanthus
  diagnostic: true
  subtypes:
  - Type I
  - Type II
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "is defined by a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus."
    explanation: GeneReviews summary supports telecanthus as a cardinal diagnostic feature of BPES.
- category: Reproductive
  name: Premature ovarian insufficiency
  description: Ovarian dysfunction in Type I BPES can progress to premature ovarian insufficiency in affected females.
  phenotype_term:
    preferred_term: Premature ovarian insufficiency
    term:
      id: HP:0008209
      label: Premature ovarian insufficiency
  subtype: Type I
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "BPES type I includes the four major features and primary ovarian insufficiency; BPES type II includes only the four major features."
    explanation: GeneReviews summary supports premature ovarian insufficiency as the defining extraocular phenotype of Type I BPES.
- category: Reproductive
  name: Female infertility
  description: Female infertility is a clinically important reproductive consequence of Type I BPES.
  phenotype_term:
    preferred_term: Female infertility
    term:
      id: HP:0008222
      label: Female infertility
  subtype: Type I
  evidence:
  - reference: PMID:31823134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There are two clinical types of BPES: type I patients have eyelid abnormalities accompanied by infertility in affected females, while type II patients only display eyelid malformations."
    explanation: Human clinical evidence supports female infertility as a hallmark feature of Type I BPES.
- category: Ocular
  name: Strabismus
  description: Strabismus is a recurrent associated ophthalmic manifestation in BPES and contributes to amblyopia risk.
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  subtypes:
  - Type I
  - Type II
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Other ophthalmic manifestations that can be associated with BPES include dysplastic eyelids, lacrimal duct anomalies, strabismus, refractive errors, and amblyopia."
    explanation: GeneReviews summary supports strabismus as an associated ophthalmic feature of BPES.
- category: Ocular
  name: Amblyopia
  description: Amblyopia is a common secondary ophthalmic complication that needs surveillance and treatment during visual development.
  phenotype_term:
    preferred_term: Amblyopia
    term:
      id: HP:0000646
      label: Amblyopia
  subtypes:
  - Type I
  - Type II
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Other ophthalmic manifestations that can be associated with BPES include dysplastic eyelids, lacrimal duct anomalies, strabismus, refractive errors, and amblyopia."
    explanation: GeneReviews summary supports amblyopia as an associated ophthalmic feature of BPES.
- category: Ocular
  name: Refractive Errors
  description: >
    Refractive errors are associated ophthalmic findings in BPES and contribute
    to amblyopia risk when not identified and corrected during visual
    development.
  phenotype_term:
    preferred_term: Refractive error
    term:
      id: HP:0000539
      label: Abnormality of refraction
  subtypes:
  - Type I
  - Type II
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Other ophthalmic manifestations that can be associated with BPES include dysplastic eyelids, lacrimal duct anomalies, strabismus, refractive errors, and amblyopia."
    explanation: >
      GeneReviews lists refractive errors among ophthalmic manifestations
      associated with BPES.
- category: Ocular
  name: Lacrimal Duct Anomalies
  description: >
    Lacrimal duct anomalies are associated ophthalmic structural findings in
    BPES and may require ophthalmologic monitoring or intervention.
  phenotype_term:
    preferred_term: Lacrimal duct anomalies
    term:
      id: HP:0011481
      label: Abnormal lacrimal duct morphology
  subtypes:
  - Type I
  - Type II
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Other ophthalmic manifestations that can be associated with BPES include dysplastic eyelids, lacrimal duct anomalies, strabismus, refractive errors, and amblyopia."
    explanation: >
      GeneReviews lists lacrimal duct anomalies among ophthalmic manifestations
      associated with BPES.
diagnosis:
- name: Clinical Ophthalmologic Diagnosis
  description: >
    BPES should be suspected from the congenital four-feature eyelid complex:
    blepharophimosis, ptosis, epicanthus inversus, and telecanthus. Clinical
    evaluation should also document visual acuity, refractive error, strabismus,
    amblyopia risk, dysplastic eyelids, and lacrimal duct anomalies.
  diagnosis_term:
    preferred_term: ophthalmologist evaluation
    term:
      id: MAXO:0000703
      label: ophthalmologist evaluation
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "is defined by a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus."
    explanation: >
      GeneReviews defines the congenital cardinal eyelid findings used for
      clinical recognition.
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Other ophthalmic manifestations that can be associated with BPES include dysplastic eyelids, lacrimal duct anomalies, strabismus, refractive errors, and amblyopia."
    explanation: >
      GeneReviews supports broader ophthalmologic assessment for associated
      visual-development risks and ocular anomalies.
- name: FOXL2 Molecular Genetic Testing
  description: >
    Molecular confirmation should use testing that can identify heterozygous
    FOXL2 pathogenic variants and pathogenic variation in the regulatory domain,
    including sequence-level variants and deletion/duplication or regulatory
    region changes when clinically indicated.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of BPES is established in a proband with suggestive findings and a heterozygous pathogenic variant in FOXL2 or its regulatory domain identified by molecular genetic testing."
    explanation: >
      GeneReviews supports molecular confirmation of BPES by FOXL2 or
      regulatory-domain testing.
- name: Endocrine and Reproductive Evaluation for Type I Risk
  description: >
    Females with BPES, especially those with Type I features or truncating FOXL2
    variants, should receive endocrine and gynecologic evaluation for ovarian
    reserve and primary ovarian insufficiency risk. Useful assessments can
    include menstrual history, FSH, AMH, antral follicle count, and fertility
    counseling before ovarian reserve declines.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: MAXO:0000487
      label: clinical assessment
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Endocrinologic and gynecologic follow up are advised for affected females."
    explanation: >
      GeneReviews supports endocrine and gynecologic surveillance for affected
      females.
  - reference: PMID:35574016
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared to non-mutation group, patients with FOXL2 mutations had elevated levels of FSH (P=0.007), decreased AMH levels (P=0.012) and less AFC (P=0.015)."
    explanation: >
      Clinical ART cohort supports FSH, AMH, and antral follicle count as
      ovarian reserve measures in FOXL2-mutant BPES.
treatments:
- name: Medial canthoplasty
  description: >
    Surgical correction of the medial canthal complex is used to address
    blepharophimosis, epicanthus inversus, and telecanthus, typically as the
    first stage of eyelid reconstruction.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  target_phenotypes:
  - preferred_term: Blepharophimosis
    term:
      id: HP:0000581
      label: Blepharophimosis
  - preferred_term: Epicanthus inversus
    term:
      id: HP:0000537
      label: Epicanthus inversus
  - preferred_term: Telecanthus
    term:
      id: HP:0000506
      label: Telecanthus
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Eyelid surgery traditionally involves a medial canthoplasty for correction of the blepharophimosis, epicanthus inversus, and telecanthus at age three to five years, typically followed a year later by ptosis correction."
    explanation: GeneReviews supports medial canthoplasty as part of standard staged reconstruction for the core BPES eyelid phenotype.
- name: Frontalis suspension surgery
  description: >
    Surgical ptosis correction, including frontalis suspension approaches, is
    used to address co-existing blepharoptosis after medial canthal correction.
    In the traditional staged approach, ptosis correction follows medial
    canthoplasty by about one year.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  target_phenotypes:
  - preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  evidence:
  - reference: PMID:35590300
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All cases were subjected to by C plasty with medial and lateral canthoplasty for correction of epicanthus and telecanthus correction followed by frontalis suspension surgery to correct the co-existing blepharoptosis."
    explanation: Retrospective surgical series supports staged frontalis suspension to correct BPES-associated ptosis.
- name: Amblyopia Prevention and Refractive Management
  description: >
    Ophthalmic follow-up should include visual acuity testing, refraction, and
    treatment of amblyopia risk through optical correction, occlusion therapy,
    and strabismus management when indicated.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Amblyopia
    term:
      id: HP:0000646
      label: Amblyopia
  - preferred_term: Refractive error
    term:
      id: HP:0000539
      label: Abnormality of refraction
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Ophthalmic follow up depends on age, procedures performed in the past, and results of visual acuity testing."
    explanation: >
      GeneReviews supports ongoing ophthalmic follow-up tied to visual acuity
      and prior procedures.
- name: Hormone replacement therapy
  description: >
    Hormone replacement therapy is used to manage Type I BPES-associated
    premature ovarian insufficiency and hypoestrogenic sequelae.
  treatment_term:
    preferred_term: hormone replacement therapy
    term:
      id: NCIT:C15599
      label: Hormone Replacement Therapy
  target_phenotypes:
  - preferred_term: Premature ovarian insufficiency
    term:
      id: HP:0008209
      label: Premature ovarian insufficiency
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Primary ovarian insufficiency is managed by hormone replacement therapy; fertility is addressed with reproductive technologies such as embryo donation, egg donation, and cryopreservation strategies."
    explanation: GeneReviews supports hormone replacement therapy as standard management for BPES-associated ovarian insufficiency.
- name: Assisted reproductive technology
  description: >
    Assisted reproductive technologies are used for fertility planning and
    treatment in affected women with Type I BPES. Counseling should include
    fertility preservation options such as oocyte or embryo cryopreservation
    before ovarian reserve declines, while recognizing that outcomes are
    heterogeneous across FOXL2 mutation classes.
  treatment_term:
    preferred_term: assisted reproductive technology
    term:
      id: NCIT:C93282
      label: Assisted Reproductive Technology
  target_phenotypes:
  - preferred_term: Female infertility
    term:
      id: HP:0008222
      label: Female infertility
  evidence:
  - reference: PMID:35574016
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Twenty-one women with BPES were screened for mutations in the FOXL2 gene and underwent assisted reproductive technology (ART) treatment."
    explanation: Human clinical study directly documents use of assisted reproductive technology in women with BPES.
- name: Bone Health Monitoring in Primary Ovarian Insufficiency
  description: >
    Type I females with hypoestrogenism from primary ovarian insufficiency need
    monitoring and prevention of estrogen-deficiency sequelae, including bone
    health assessment and coordination with hormone replacement therapy.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Premature ovarian insufficiency
    term:
      id: HP:0008209
      label: Premature ovarian insufficiency
  evidence:
  - reference: PMID:24905063
    reference_title: "Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Women with primary ovarian insufficiency have significantly lower serum estradiol and T levels compared with regularly menstruating women. They also have significantly reduced bone mineral density (BMD)."
    explanation: >
      Primary ovarian insufficiency is associated with reduced bone mineral
      density, supporting bone-health monitoring in Type I BPES with POI.
- name: Genetic Counseling
  description: >
    Counsel affected individuals and families about autosomal dominant
    inheritance, the 50% transmission risk to offspring, variable Type I/II
    expressivity, de novo cases, and availability of prenatal or
    preimplantation genetic testing once the familial variant is known.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Each child of an individual with BPES has a 50% chance of inheriting the pathogenic variant."
    explanation: GeneReviews supports counseling about autosomal dominant recurrence risk.
  - reference: PMID:20301614
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Once the BPES-causing pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for BPES are possible."
    explanation: >
      GeneReviews supports reproductive genetic counseling after the familial
      FOXL2 pathogenic variant is identified.
references:
- reference: PMID:20301614
  title: "Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

1

PMID:20301614

Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome.

No top-level findings curated for this source.

Deep Research

1

Manual Pubmed Review ▸

Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome: Mechanistic Summary

n/a 7 citations 2026-04-14T07:58:00Z

Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome: Mechanistic Summary

Disease-root framing

BPES is best curated as a disease root with subtype structure, not as a flat eyelid phenotype bucket. Recent clinical review data explicitly separate BPES-I from BPES-II by the presence or absence of primary ovarian insufficiency (PMID:41555764). Review literature also emphasizes that both subtypes share the same congenital eyelid complex and that genotype alone does not fully determine subtype assignment (PMID:33806295).

Genetics and inheritance

BPES is a predominantly autosomal dominant disorder caused by heterozygous pathogenic variants in FOXL2 (PMID:33806295; PMID:20301614). FOXL2 is the single causal anchor for the classic root disease and should be modeled as the causative gene in the disorder entry.

Core pathophysiology

Two mechanistic axes repeatedly emerge from the literature:

Eyelid developmental dysregulation FOXL2 variants impair transcriptional control of eyelid-development targets. Functional data show failure of mutant FOXL2 proteins to transactivate OSR2, which is consistent with the eyelid malformation phenotype (PMID:33796131).
Ovarian reserve maintenance failure in Type I FOXL2 dysfunction also affects ovarian biology. Functional assays show loss of FOXL2 repression on CYP19A1 and CCND2 promoters (PMID:31823134), and clinical cohorts demonstrate diminished ovarian reserve with adverse assisted reproductive technology outcomes in FOXL2-mutant BPES women (PMID:35574016).

Variant class influences severity but does not create a deterministic rule. Truncating FOXL2 variants are enriched in BPES-I, whereas polyalanine-region changes are more often associated with BPES-II (PMID:41555764; PMID:33806295).

Hallmark phenotypes

The four cardinal BPES features present at birth are:

Blepharophimosis
Ptosis
Epicanthus inversus
Telecanthus

These are explicitly defined in GeneReviews (PMID:20301614). Associated ocular features include strabismus, refractive errors, and amblyopia (PMID:20301614). Type I additionally carries primary ovarian insufficiency and female infertility risk (PMID:20301614; PMID:31823134).

Treatment-relevant findings

Management is multidisciplinary and naturally separates into ocular and reproductive domains:

Staged eyelid surgery: medial canthoplasty for blepharophimosis, epicanthus inversus, and telecanthus, followed later by ptosis correction (PMID:20301614).
Frontalis suspension / canthoplasty approaches: clinical series support staged canthoplasty plus frontalis suspension for correction of epicanthus, telecanthus, and coexisting blepharoptosis (PMID:35590300).
Hormone replacement therapy for BPES-I-associated ovarian insufficiency (PMID:20301614).
Assisted reproductive technology and fertility planning for affected women with FOXL2 mutations, though outcomes are heterogeneous (PMID:35574016; PMID:20301614).

References

PMID:20301614
PMID:31823134
PMID:33796131
PMID:33806295
PMID:35574016
PMID:35590300
PMID:41555764

Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Source YAML

References & Deep Research

References

Deep Research

Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome: Mechanistic Summary

Disease-root framing

Genetics and inheritance

Core pathophysiology

Hallmark phenotypes

Treatment-relevant findings

References